Stanley Laman Group Ltd. Lowers Stock Holdings in Stryker Corporation $SYK

Stanley Laman Group Ltd. lessened its holdings in shares of Stryker Corporation (NYSE:SYK) by 33.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 801 shares of the medical technology company’s stock after selling 401 shares during the quarter. Stanley Laman Group Ltd.’s holdings in Stryker were worth $317,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in SYK. Brighton Jones LLC lifted its position in Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Stryker by 16.4% during the 1st quarter. GAMMA Investing LLC now owns 5,574 shares of the medical technology company’s stock worth $2,075,000 after acquiring an additional 785 shares during the period. Kingswood Wealth Advisors LLC boosted its position in shares of Stryker by 21.7% in the first quarter. Kingswood Wealth Advisors LLC now owns 1,489 shares of the medical technology company’s stock worth $555,000 after acquiring an additional 265 shares during the last quarter. Institute for Wealth Management LLC. acquired a new stake in shares of Stryker in the first quarter worth approximately $205,000. Finally, United Advisor Group LLC purchased a new stake in Stryker in the first quarter valued at approximately $219,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Wells Fargo & Company lifted their price target on shares of Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a report on Friday, August 1st. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research report on Saturday. UBS Group set a $408.00 price target on Stryker in a research report on Monday, October 13th. Redburn Partners set a $420.00 price target on Stryker in a research note on Thursday, September 18th. Finally, Needham & Company LLC lifted their price objective on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Fifteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $431.76.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Stryker Trading Up 1.5%

NYSE:SYK opened at $374.67 on Friday. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The business’s 50-day moving average is $379.40 and its two-hundred day moving average is $378.77. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The firm has a market capitalization of $143.24 billion, a PE ratio of 49.63, a price-to-earnings-growth ratio of 2.70 and a beta of 0.94.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. During the same quarter last year, the firm earned $2.81 earnings per share. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s dividend payout ratio (DPR) is currently 44.50%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.